Interventions to increase adiponectin may be associated with increased coronary heart disease in older adults

Future Cardiology

Volumn 5, Issue 1, 2009, Pages 19-22

  Wannamethee, S Goya ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN;

AGE DISTRIBUTION; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY RISK; ELDERLY CARE; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK ASSESSMENT; WEIGHT REDUCTION;

EID: 66949157990     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.5.1.19     Document Type: Article

References (30)

1. Kizer JR, Barzilay JI, Kuller LH, Gottdiener JS: Adiponectin and risk of coronary heart disease in older men and women. J. Clin. Endocrinol. Metab. 93, 3357-3364 (2008).
2. Lihn AS, Pedersen SB, Richelsen B: Adiponectin: action. Regulation and association to insulin sensitivity. Obes. Rev. 6, 13-21 (2005).
3. Szmitko H, Tech H, Stewart DJ, Verna S: Adiponectin and cardiovascular disease: state of the art? Am. J. Physiol. Heart Circ. Physiol. 292, H1655-H1663 (2007).
4. Chandran M, Phillips SA, Ciaraldi T, Henry RR: Adiponectin: more than just another fat cell hormone? Reviews/commentaries. Diabetes Care 26, 2442-2450 (2003).
5. Ouchi N, Kihara S, Arita Y et al.: Adiponectin, an adipocyte derived plasma protein, inhibits endothelial NF-κB signalling through a cAMP-dependent pathway. Circulation 102, 1296-1301 (2000).
6. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB: Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291, 1730-1737 (2004).
7. Sattar N, Wannamethee G, Sarwar N et al.: Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 114(7), 623-629 (2006).
8. Rothenbacher D, Brenner H, Marz W, Koenig W: Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur. Heart J. 26, 1640-1646 (2005).
9. Koenig W, Khuseyinova N, Baumert J, Meisinger C, Löwel H: Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: result's from the 18-year follow-up of a large cohort from southern Germany. J. Am. Coli. Cardiol. 48(???), 1369-1377 (2006).
10. Frystyk J, Berne C, Berglund L, Jensevik K, Flyvbjerg A, Zethelius B: Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J. Clin. Endocrinol. Metab. 92(2), 571-576 (2007).
11. Kanaya AM, Wassel Fyr C, Vittinghoff E et al.; Health ABC Study: Serum adiponectin and coronary heart disease risk in older Black and White Americans. J. Clin. Endocrinol. Metab. 91(12), 5044-5050 (2006).
12. Schulze MB, Shai I, Rimm EB et al.: Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 54, 534-539 (2005).
13. Lawlor DA, Davey Smith G, Ebrahim S, Thompson C, Sattar N: Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary, heart disease in women. J. Clin. Endocrinol. Metab. 90, 5677-5683 (2005).
14. Lindsay RS, Resnick HE, Zhu J et al.: Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler. Thromb. Vasc. Biol. 25, E15-E16 (2005).
15. Kistorp C, Faber J, Galatius S et al.: Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 112, 1756-1762 (2005).
16. George J, Patel S, Wexler D et al.: Circulating adiponectin levels predict outcome in patients with severe congestive heart failure. Heart 92(10), 1420-1424 (2006).
17. Cavusoglu E, Ruwende C, Chopra V et al.: Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur. Heart J. 27(19), 2300-2309 (2006).
18. Pilz S, Mangge H, Wellnitz et al.: Adiponectin and mortality in patients undergoing coronary angiography. J. Clin. Endocrin. Metab. 91, 4277-4286 (2006).
19. Schnabel R, Messow CM, Lubos E et al.: Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study. Eur. Heart J. 29(5), 649-657 (2008).
20. Menon V, Li L, Wang X et al.: Adiponectin and mortality in patients with chronic kidney disease. J. Am. Soc. Nephrol. 17(9), 2599-2606 (2006).
21. Laughlin GA, Barrett-Connor E, May S, Langenberg C: Association of adipoenctin and coronary heart disease and mortality: the Rancho Bernardo study. Am. J. Epidemiol. 165, 164-174 (2007).
22. Wannamethee SG, Whincup PH, Lennon L, Sattar N: Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch. Intern. Med. 167, 1510-1517 (2007).
23. Dekker JM, Funahashi T, Nijpels G et al.: Prognostic value of adiponectin for cardiovascular disease and mortality. J. Clin. Endocrinol. Metab. 93(4), 1489-1496 (2008).
24. Isobe T, Saitoh S, Takagi S et al.: Influence of gender, age and renal function on plasma adiponectin level: the Tanno and Sobetsu. study. Eur. J. Endocrinol. 153, 91-98 (2005).
25. Teoh H, Strauss MH, Szmitko PE, Verma S: Adiponectin and myocardial infarction: a paradox or a paradigm: Eur. Heart J. 27(19), 2266-2268 (2006).
26. von Eynatten M, Hamann A, Twardella D, Nawroth PP, Brenner H, Rothenbacher D: Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease. Clin. Chem. 52(5), 853-859 (2006).
27. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R: N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N. Engl. J. Med. 352, 666-675 (2005).
28. Sattar N, Watt P, Cherry L, Ebrahim S, Davey Smith G, Lawlor DA: High molecular weight adiponectin is not associated with incident coronary heart disease in older women: a nested prospective case-control study. J. Clin. Endocrinol. Metab. 93(5), 1846-1849 (2008).
29. von Eynatten M, Hamann A, Twardella D, Nawroth PP, Brenner H, Rothenbacher D: Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease. Eur. Heart J. 29(10), 1307-1315 (2008).
30. Sattar N, Nelson SM: Adiponectin, diabetes, and coronary heart disease in older persons: unraveling the paradox. J. Clin. Endocrinol. Metab. 93(9), 3299-3301 (2008).